Manufacturer
L.B.S. LABS LTD PART
Contents
Diclofenac Sodium
Indication
Postoperative pain, Acute pain, Acute gout, Acute pain, Osteoarthritis, Pain after accidental trauma, Postoperative pain, Rheumatoid arthritis, Renal colic
Instruction
Administer via IM injection/Intragluteal injection/ IV Bolus injection/IV infusion.
Drug interaction
Increased risk of gastrointestinal ulceration, perforation or haemorrhage with other corticosteroids, SSRIs. Increased risk CV-related adverse reactions with cardiac glycosides. Increased risk of hyperkalaemia and renal toxicity with ACE inhibitors, diuretics, ciclosporin, tacrolimus. Increased risk of haematological toxicity with zidovudine. Increased levels and risk of toxicity with digoxin, lithium, methotrexate, pemetrexed, phenytoin. Decreased effect with colestipol, cholestyramine. Decrease effect of mifepristone. Increased peak plasma concentration with CYP2C9 inhibitors e.g. voriconazole.Potentially Fatal: Increased risk of gastrointestinal ulceration, perforation or haemorrhage with other NSAIDs (e.g. aspirin), antiplatelets, anticoagulants (e.g. warfarin).
Malaysia
